Floatz logo

(+)-VINCRISTINE

Ovarian Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Ovarian Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2B
IERAMILIMAB
Novartis Pharmaceuticals
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Cediranib
M.D. Anderson Cancer Center
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 10 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →